Tags

Type your tag names separated by a space and hit enter

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
PLoS One 2019; 14(10):e0223181Plos

Abstract

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this retrospective multicentre study was to evaluate the impact on lipids of switching from rilpivirine (RPV)/ emtricitabine (FTC)/TDF to RPV/FTC/TAF in a cohort of HIV-1 infected patients. Total cholesterol (TC), high density lipoproteins (HDL) and low density lipoproteins (LDL) were compared at the moment of the switch and at the first following evaluation, by using paired t-test. Overall, 573 patients were considered, 99% with HIV-RNA <50 copies/ml, with mean age of 49.7 (±0.4) years and median 13.4 (6.9-22.5) years of HIV infection. In the study population with available data (431/573, 75%), mean TC changed from 173 ±1.7 to 188 ±1.8 mg/dl; mean HDL from 46 ±0.7 to 51± 0.7 mg/dl; mean LDL from 111 ±1.5 to 120 ±1.8 mg/dl (p<0.0001 for all). Neither LDL/HDL nor TC/HDL ratio changed significantly, with LDL/HDL from 2.6 ±0.5 to 2.5 ±0.5 (p = 0.12) and TC/HDL from 4.0 ±0.6 to 3.9 ±0.6 (p = 0.11). In patients with baseline diagnosis of hypercholesterolemia (TC>200 mg/dl, N = 87), there was no significant change in TC (224 ±2.2 to 228 ±3.4 mg/dl, p = 0.286) or LDL (150±2.5 to 151±3.2 mg/dl, p = 0.751), while HDL increased from 51 ±1.6 to 55 ±1.7 mg/dl (p<0.0001) and both LDL/HDL and TC/HDL ratio decreased significantly, from 3.2±0.1 to 3.0 ±0.1 (p = 0.025) and from 4.7±0.1 to 4.4 ±0.1 (p = 0.004). In this real life study, a slight increase in lipids was found after switching from RPV/FTC/TDF to RPV/FTC/TAF, but these results were not confirmed in people with hypercholesterolemia, in which lipids did not change and LDL/HDL and TC/HDL ratio decreased.

Authors+Show Affiliations

Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy.Infectious Diseases Clinic, Policlinico San Martino Hospital, Genoa, Italy.Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy. Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy.Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy.Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genova, Genoa, Italy.Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genova, Genoa, Italy.Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31603906

Citation

Taramasso, Lucia, et al. "Lipid Profile Changings After Switching From Rilpivirine/tenofovir Disoproxil Fumarate/emtricitabine to Rilpivirine/tenofovir Alafenamide/emtricitabine: Different Effects in Patients With or Without Baseline Hypercholesterolemia." PloS One, vol. 14, no. 10, 2019, pp. e0223181.
Taramasso L, Di Biagio A, Riccardi N, et al. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. PLoS ONE. 2019;14(10):e0223181.
Taramasso, L., Di Biagio, A., Riccardi, N., Briano, F., Di Filippo, E., Comi, L., ... Maggiolo, F. (2019). Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. PloS One, 14(10), pp. e0223181. doi:10.1371/journal.pone.0223181.
Taramasso L, et al. Lipid Profile Changings After Switching From Rilpivirine/tenofovir Disoproxil Fumarate/emtricitabine to Rilpivirine/tenofovir Alafenamide/emtricitabine: Different Effects in Patients With or Without Baseline Hypercholesterolemia. PLoS ONE. 2019;14(10):e0223181. PubMed PMID: 31603906.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. AU - Taramasso,Lucia, AU - Di Biagio,Antonio, AU - Riccardi,Niccolò, AU - Briano,Federica, AU - Di Filippo,Elisa, AU - Comi,Laura, AU - Mora,Sara, AU - Giacomini,Mauro, AU - Gori,Andrea, AU - Maggiolo,Franco, Y1 - 2019/10/11/ PY - 2019/04/05/received PY - 2019/09/16/accepted PY - 2019/10/12/entrez PY - 2019/10/12/pubmed PY - 2019/10/12/medline SP - e0223181 EP - e0223181 JF - PloS one JO - PLoS ONE VL - 14 IS - 10 N2 - Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this retrospective multicentre study was to evaluate the impact on lipids of switching from rilpivirine (RPV)/ emtricitabine (FTC)/TDF to RPV/FTC/TAF in a cohort of HIV-1 infected patients. Total cholesterol (TC), high density lipoproteins (HDL) and low density lipoproteins (LDL) were compared at the moment of the switch and at the first following evaluation, by using paired t-test. Overall, 573 patients were considered, 99% with HIV-RNA <50 copies/ml, with mean age of 49.7 (±0.4) years and median 13.4 (6.9-22.5) years of HIV infection. In the study population with available data (431/573, 75%), mean TC changed from 173 ±1.7 to 188 ±1.8 mg/dl; mean HDL from 46 ±0.7 to 51± 0.7 mg/dl; mean LDL from 111 ±1.5 to 120 ±1.8 mg/dl (p<0.0001 for all). Neither LDL/HDL nor TC/HDL ratio changed significantly, with LDL/HDL from 2.6 ±0.5 to 2.5 ±0.5 (p = 0.12) and TC/HDL from 4.0 ±0.6 to 3.9 ±0.6 (p = 0.11). In patients with baseline diagnosis of hypercholesterolemia (TC>200 mg/dl, N = 87), there was no significant change in TC (224 ±2.2 to 228 ±3.4 mg/dl, p = 0.286) or LDL (150±2.5 to 151±3.2 mg/dl, p = 0.751), while HDL increased from 51 ±1.6 to 55 ±1.7 mg/dl (p<0.0001) and both LDL/HDL and TC/HDL ratio decreased significantly, from 3.2±0.1 to 3.0 ±0.1 (p = 0.025) and from 4.7±0.1 to 4.4 ±0.1 (p = 0.004). In this real life study, a slight increase in lipids was found after switching from RPV/FTC/TDF to RPV/FTC/TAF, but these results were not confirmed in people with hypercholesterolemia, in which lipids did not change and LDL/HDL and TC/HDL ratio decreased. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/31603906/Lipid_profile_changings_after_switching_from_rilpivirine/tenofovir_disoproxil_fumarate/emtricitabine_to_rilpivirine/tenofovir_alafenamide/emtricitabine:_Different_effects_in_patients_with_or_without_baseline_hypercholesterolemia L2 - http://dx.plos.org/10.1371/journal.pone.0223181 DB - PRIME DP - Unbound Medicine ER -